PRESS RELEASE
Barcelona, Spain – 13 JULY 2017 – AVX PHARMA, a clinical stage biopharmaceutical company focused on the development of novel therapies for Dry Eye Syndrome, today announced the initiation of a Phase 2 clinical trial, evaluating the safety and efficacy of AVX-012 Ophthalmic Solution in patients with mild-to-moderate Dry Eye Syndrome.
PRESS RELEASE
Barcelona, Spain – 1 JULY 2016 – AVX PHARMA, an ophthalmology biotech company focused on developing novel therapies for Dry Eye Syndrome, today announced the submission of a Clinical Trial Application (CTA) to the Spanish Competent Authority, requesting clearance to initiate a Phase I/II clinical trial investigating the use of AVX-012 Ophthalmic Solution to treat patients suffering from mild to moderate Dry Eye Syndrome (DES).
PRESS RELEASE
Barcelona, March 3rd, 2015. AVIZOREX PHARMA, SL, a Venture Capital backed biopharmaceutical company developing novel therapeutics for Dry Eye Disease, announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for compositions and methods of treatment covering AVX-012, a topical treatment for Dry Eye with a new mechanism of action currently undergoing late-stage preclinical studies.
PRESS RELEASE
Elche, 13/10/2014. Inveready Innvierte Biotech II, the specialized venture capital fund by Inveready Technology Investment Group, has invested in AVIZOREX, an ophthalmology biotech company founded in 2013 by Patrick Tresserras and Professor Carlos from Instituto de Neurociencias de Alicante.